Business
Lipocine Announces Presentations on TLANDO™ at AUA Virtual Experience 2020
SALT LAKE CITY, May 15, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, May 15, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO™ will be presented at the American Urological Association (\"AUA\") Virtual Experience, to take place May 15-17, 2020. TLANDO is an oral testosterone replacement therapy (\"TRT\") product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.\n\n \n \n \n \n \n \n\n \nAbstract Number: MP45-14 Title: Impact of a new oral testosterone undecanoate on blood pressure and cardiovascular riskPresenter: Mohit Khera, MD Session Type: Poster SessionSession Title: Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II Abstract Number: MP45-15 Title: A novel oral testosterone therapy restores testosterone to eugonadal levels without dose titrationPresenter: Martin Miner, MDSession Type: Poster SessionSession Title: Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II Abstract Number: PD26-05 Title: Effects of a new oral testosterone undecanoate (TLANDO) therapy on liverPresenter: Irwin Goldstein, MDSession Type: Oral Podium SessionSession Title: Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy IThe abstracts, posters and podium slides are published today on the AUA website.\nAbout LipocineLipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. Lipocine has resubmitted its NDA to the FDA for TLANDO and has a PDUFA date of August 28, 2020. LPCN 1144, an oral product of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of pre-cirrhotic NASH. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 c...